NCT00704132View on ClinicalTrials.gov

Sitagliptin Mechanism of Action Study in Patients With Type 2 Diabetes Mellitus (0431-059)

PHASE1CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

February 14, 2007

Primary Completion Date

April 28, 2010

Study Completion Date

April 28, 2010

Conditions
Type 2 Diabetes Mellitus (T2DM)
Interventions
DRUG

Comparator: sitagliptin phosphate

Sitagliptin tablet 100 mg, administered once daily before the morning meal.

DRUG

Comparator: placebo (unspecified)

Matching placebo tablet, administered once daily before the morning meal.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00704132 - Sitagliptin Mechanism of Action Study in Patients With Type 2 Diabetes Mellitus (0431-059) | Biotech Hunter | Biotech Hunter